Cenobamate in partial-onset seizures: a profile of its use
Any type of resource available online.
Compliance with ethical standards
Funding The preparation of this review was not supported by any external funding.
Conflict of interest Sheridan M. Hoy is an employee of Adis International Ltd./Springer Nature, is responsible for the article content and declares no conflicts of interest.
Cenobamate (XCOPRI®), a novel tetrazole alkyl carbamate derivative, is approved in the USA for use as monotherapy and adjunctive therapy in adults with focal seizures (also known as partial-onset seizures). Its use (within the recommended dosage of ≤ 400 mg/day) significantly reduced focal seizure frequency relative to the use of placebo in short-term (≤ 18 weeks) multinational, phase 2 studies in adults with focal seizures, with antiepileptic benefits appearing to be sustained over the longer-term (30 months). Cenobamate appears to have low abuse potential and to be generally well tolerated over the short- and longer-term (up to 79 months), with most treatment-emergent adverse events (TEAEs) being mild or moderate in severity. The most frequently reported TEAEs (somnolence, dizziness and fatigue) were CNS related, dose dependent and similar to those seen with other anti-seizure medications.